Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of XAB05 in healthy adults
NL-OMON50582Phase 1Active, not recruiting
- Sponsor
- Xenothera
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of XAB05 in bacterial disease (2 arms), sponsored by Xenothera. Primary endpoint: Safety and tolerability. Started Jan 2022; status: active, not recruiting.
02
Drugs
XAB05
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON50582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50582.